Search research articles
Contact Us
Filters
Showing results (71-80 of 191) with videos related to
Page
of 20
Sort By:
European Urology Oncology
|
August 22, 2025
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer
Fred Saad, Alberto Briganti, Kunhi Parambath Haresh, et al.
The Journal of Urology
|
May 3, 2024
A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial
Yair Lotan, Siamak Daneshmand, Neal Shore, et al.
European Urology Oncology
|
April 9, 2026
Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials
Alicia K Morgans, Sara Ekberg, Martin Boegemann, et al.
Clinical Pharmacology in Drug Development
|
May 17, 2024
A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk
Chenna Keshava Reddy Sannala, Carol MacLean, Finn Larsen, et al.
Targeted Oncology
|
May 21, 2025
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation
Fred Saad, Andrew J Armstrong, Neal Shore, et al.
Current Medical Research and Opinion
|
December 11, 2013
Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer
Neal Shore, Raoul Concepcion, Daniel Saltzstein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 25, 2025
Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis
Neal Shore, Alicia K Morgans, Martin Boegemann, et al.
Frontiers in Medicine
|
January 9, 2023
Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer
Joe M O'Sullivan, Rana R McKay, Kambiz Rahbar, et al.
Future Oncology (London, England)
|
April 28, 2021
Real-world genetic testing patterns in metastatic castration-resistant prostate cancer
Neal Shore, Raluca Ionescu-Ittu, Lingfeng Yang, et al.
Urology Practice
|
June 15, 2023
Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice
Neal Shore, Jason Hafron, Timothy Langford, et al.
Page
of 20
Search research articles
Search
Showing results (71-80 of 191) with videos related to
Sort By:
Page
of 20
European Urology Oncology
|
August 22, 2025
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer
Fred Saad, Alberto Briganti, Kunhi Parambath Haresh, et al.
The Journal of Urology
|
May 3, 2024
A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial
Yair Lotan, Siamak Daneshmand, Neal Shore, et al.
European Urology Oncology
|
April 9, 2026
Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials
Alicia K Morgans, Sara Ekberg, Martin Boegemann, et al.
Clinical Pharmacology in Drug Development
|
May 17, 2024
A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk
Chenna Keshava Reddy Sannala, Carol MacLean, Finn Larsen, et al.
Targeted Oncology
|
May 21, 2025
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation
Fred Saad, Andrew J Armstrong, Neal Shore, et al.
Current Medical Research and Opinion
|
December 11, 2013
Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer
Neal Shore, Raoul Concepcion, Daniel Saltzstein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 25, 2025
Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis
Neal Shore, Alicia K Morgans, Martin Boegemann, et al.
Frontiers in Medicine
|
January 9, 2023
Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer
Joe M O'Sullivan, Rana R McKay, Kambiz Rahbar, et al.
Future Oncology (London, England)
|
April 28, 2021
Real-world genetic testing patterns in metastatic castration-resistant prostate cancer
Neal Shore, Raluca Ionescu-Ittu, Lingfeng Yang, et al.
Urology Practice
|
June 15, 2023
Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice
Neal Shore, Jason Hafron, Timothy Langford, et al.
Page
of 20